Products
Oxelumab Biosimilar Monoclonal Antibody (OX40L) for Research
Pre-Made Oxelumab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Oxelumab is a human monoclonal antibody designed for the treatment of asthma.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-417-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Oxelumab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody |
| INN Name | Oxelumab |
| Target | OX40 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Genentech;Genmab;Roche |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Allergic asthma;Allergic rhinitis |
| Development Tech | na |
About target - TNFSF4
1. Protein Tumor necrosis factor ligand superfamily member 4
2. Gene TNFSF4
3. Organism Homo sapiens (Human)
Function
Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production.
